Find Vatiquinone manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1213269-98-7, Epi-743, Alpha-tocotrienol quinone, Epi 743, Alpha tocotrienol quinone, .alpha.-tocotrienol quinone
Molecular Formula
C29H44O3
Molecular Weight
440.7  g/mol
InChI Key
LNOVHERIIMJMDG-XZXLULOTSA-N
FDA UNII
6O85FK9I0X

Vatiquinone
Vatiquinone has been investigated for the treatment and prevention of Retinopathy, Rett Syndrome, Genetic Disease, Noise-induced Hearing Loss, and Methylmalonic Aciduria and Homocystinuria,Cblc Type.
1 2D Structure

Vatiquinone

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione
2.1.2 InChI
InChI=1S/C29H44O3/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8,32)19-17-26-25(7)27(30)23(5)24(6)28(26)31/h12,14,16,32H,9-11,13,15,17-19H2,1-8H3/b21-14+,22-16+/t29-/m1/s1
2.1.3 InChI Key
LNOVHERIIMJMDG-XZXLULOTSA-N
2.1.4 Canonical SMILES
CC1=C(C(=O)C(=C(C1=O)C)CCC(C)(CCC=C(C)CCC=C(C)CCC=C(C)C)O)C
2.1.5 Isomeric SMILES
CC1=C(C(=O)C(=C(C1=O)C)CC[C@@](C)(CC/C=C(\C)/CC/C=C(\C)/CCC=C(C)C)O)C
2.2 Other Identifiers
2.2.1 UNII
6O85FK9I0X
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Alpha-tocotrienol Quinone

2. Epi-743

2.3.2 Depositor-Supplied Synonyms

1. 1213269-98-7

2. Epi-743

3. Alpha-tocotrienol Quinone

4. Epi 743

5. Alpha Tocotrienol Quinone

6. .alpha.-tocotrienol Quinone

7. 6o85fk9i0x

8. 2,5-cyclohexadiene-1,4-dione, 2-((3r,6e,10e)-3-hydroxy-3,7,11,15-tetramethyl-6,10,14-hexadecatrien-1-yl)-3,5,6-trimethyl-

9. 2-((r,6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione

10. Vatiquinone [usan]

11. Vatiquinone [usan:inn]

12. Unii-6o85fk9i0x

13. Vatiquinone [inn]

14. Vatiquinone [jan]

15. Vatiquinone (jan/usan)

16. Schembl503125

17. (r)-alpha-tocotrienol Quinone

18. Chembl1812161

19. Schembl14639355

20. Dtxsid90153231

21. Bcp21072

22. Ex-a5566

23. Db11917

24. 2-[(3r,6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione

25. Hy-16772

26. Cs-0012384

27. D10407

28. A937320

29. Q27265220

30. Epi 743;epi743; Vatiquinone; Alpha-tocotrienol Quinone

31. 2-((3r,6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione

32. 2-[(3r,6e,10e)-3-hydroxy-3,7,11,15-tetramethyl-6,10,14-hexadecatrien-1-yl]-3,5,6-trimethyl-2,5-cyclohexadiene-1,4-dion

2.4 Create Date
2010-07-06
3 Chemical and Physical Properties
Molecular Weight 440.7 g/mol
Molecular Formula C29H44O3
XLogP37.4
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count3
Rotatable Bond Count12
Exact Mass440.32904526 g/mol
Monoisotopic Mass440.32904526 g/mol
Topological Polar Surface Area54.4 Ų
Heavy Atom Count32
Formal Charge0
Complexity857
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count2
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of Leigh syndrome


Treatment of mitochondrial disease


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty